EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI
Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
ACC: Empagliflozin Does Not Cut Risk for Heart Failure After Acute MI
WEDNESDAY, April 10, 2024 -- Empagliflozin does not reduce the risk for first hospitalization for heart failure or death among patients at increased risk for heart failure after acute myocardial infarction, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 10, 2024 Category: Pharmaceuticals Source Type: news
ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI
MONDAY, April 8, 2024 -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2024 Category: Pharmaceuticals Source Type: news
Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Empagliflozin Fails to Reduce Events After Acute MI Empagliflozin Fails to Reduce Events After Acute MI
Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2024 Category: Consumer Health News Tags: Cardiology Source Type: news
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
One of the biggest themes in the pharmaceutical market right now is weight-loss treatments. Demand is off the charts for medications including Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Jardiance, and Zepbound. That's a long list of treatments, isn't it? What you might not know, however, is…#saxenda #novonordisk #nvo #elililly #lly #lilly #vikingtherapeutics #glp1 #gip #fda (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2024 Category: Consumer Health News Source Type: news
Better Buy: Eli Lilly vs. Viking Therapeutics
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of Viking by market cap and boasts a long list of approved medicines and an impressive track record of…#comparingelililly #lly #elililly #type2 #glp1 #fda #jardiance #omvoh #jaypirca #vk2809 (Source: Reuters: Health)
Source: Reuters: Health - March 3, 2024 Category: Consumer Health News Source Type: news
Empagliflozin Sheds Liver Fat in People With and Without T2D Empagliflozin Sheds Liver Fat in People With and Without T2D
Empagliflozin reduced liver fat content in patients with obesity and patients with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 22, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease
The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of chronic kidney disease (CKD). This approval allows nephrologists and cardiologists to use Jardiance for eligible CKD patients, reducing hospitalizations and addressing unmet medical needs. (Source: The Economic Times)
Source: The Economic Times - February 14, 2024 Category: Consumer Health News Source Type: news
Will Kidney Disease Patients Finally Receive New Drug Class? Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news
NICE draft advice backs further treatment option for heart failure patients
NICE has issued final draft guidance recommending empagliflozin as an option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. (Source: GP Online News)
Source: GP Online News - October 5, 2023 Category: Primary Care Tags: NICE Guidelines Source Type: news
Drug Makers Agree to Negotiate With Medicare on Prices of 10 Medications
President Biden at the White House on Monday. The first negotiations will be over 10 drugs selected by the administration, including blood thinners Eliquis and Xarelto and the diabetes drugs Jardiance and Januvia. The pharmaceutical companies said they would begin talks even as several of them…#xarelto #medicare #karinejeanpierre #maryland #democrats #republicans (Source: Reuters: Health)
Source: Reuters: Health - October 3, 2023 Category: Consumer Health News Source Type: news
Drugmakers opt in to Medicare drug price negotiations
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the…#eliquis #provo #utah #medicare #jardiance #boehringeringelheim #xarelto #januvia #farxiga #enbrel (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2023 Category: Consumer Health News Source Type: news
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK ’s Drugs
This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly (epcoritamab) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA approved Lilly’s LLY diabetes drug, Jardiance (empagliflozin), for expanded use in chronic kidney disease…#europeancommission #abbvies #fda #lilly #lly #sanofi #dupixent #merck #pah #jnj (Source: Reuters: Health)
Source: Reuters: Health - September 30, 2023 Category: Consumer Health News Source Type: news
Empagliflozin Gets FDA Nod for CKD Without T2D or HF Empagliflozin Gets FDA Nod for CKD Without T2D or HF
The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2023 Category: Cardiology Tags: Nephrology News Alert Source Type: news
